The Brownfield M&M contract is a significant1 five-year extension to the original engineering, procurement, and construction (EPC) enabling agreement awarded in 2015. Aker Solutions has delivered platform-wide upgrades and modifications to the Hebron platform since 2015 and has provided multi-disciplinary services to the East Coast Atlantic region for more than 30 years.
“We will leverage our multi-discipline Project Execution Model to deliver fit-for-purpose solutions with speed and precision, ensuring successful outcomes while reducing costs,” said Paal Eikeseth, Executive Vice President and head of Aker Solutions’ Life Cycle Business.
The work will be led from Aker Solutions’ location in St. John’s, Newfoundland and Labrador, where the company has increased its staff from 100 to 350 employees in recent years.
“We are pleased to continue our collaboration with ExxonMobil Properties, as operator of the Hebron platform, offshore Newfoundland and Labrador. Canada is a key market for us, where we take a long-term view and continue to deliver strong customer value through our capabilities,” said Eikeseth.
The contract will be booked as an order intake in the fourth quarter of 2025 in the Life Cycle segment.
1Aker Solutions defines a significant contract as being between NOK 1.5 billion and NOK 2.5 billion.
Samsung Electronics today announced that it has completed the acquisition of FläktGroup, Europe’s largest HVAC company.
Following the acquisition, Samsung plans to leverage FläktGroup’s production and sales units to expand R&D and strengthen the supply chain, progressively integrating products and services to maximize synergies. FläktGroup’s subsidiaries will also be a part of Samsung Electronics, including Woods Air Movement, which provides ventilation and fire safety systems, SEMCO, which specializes in air handling and flow solutions, and SE-Elektronic which delivers tailored advanced automation systems. Meanwhile, FläktGroup’s name, existing management, personnel and facilities will be maintained, operating it as an independent subsidiary to preserve its technological expertise and brand identity.
“This marks a strategic move for Samsung, aimed at leading the global HVAC and data center markets,” said TM Roh, President and Acting Head of the Device eXperience (DX) Division at Samsung Electronics. “By merging FläktGroup’s technological expertise with Samsung’s AI platforms, we aim to set a new benchmark in the industry, delivering innovative solutions to customers.”
Through this acquisition, Samsung will strategically nurture the HVAC business as a new growth engine within its DX Division. The company plans to continuously invest in commercial HVAC solutions and expand into high-growth sectors such as AI data centers.
As demand for large-scale air conditioning systems grows in Korea, North America, and Europe — including large factories, commercial complexes, marine, hospitals, and biopharmaceutical facilities — the company aims to establish a robust supply chain in each region and enhance its service capabilities. Moreover, Samsung formed a joint venture with Lennox last year to further secure its presence in the North American market, and expects that the acquisition of FläktGroup will strengthen the company’s position with expanded expertise to HVAC solutions.
Additionally, by integrating FläktGroup’s advanced HVAC control systems with Samsung’s building management platforms such as SmartThings Pro and b.IoT, Samsung will explore new opportunities in smart building solutions and energy efficiency.
“Joining Samsung will accelerate FläktGroup’s global market expansion and drive technological innovation,” commented Trevor Young, CEO of FläktGroup. “The synergy between our companies will be a major turning point in developing future-oriented HVAC solutions.”
With over a century of history and technical expertise, FläktGroup supplies central air conditioning and precision cooling solutions for several industries across global markets. The company operates more than 10 production bases for central HVAC products and has built an extensive sales and service network across Europe, the Americas, the Middle East and Asia.
Based on these capabilities, the company has participated in the Stargate Project and partnered with other major hyperscale customers. It has also developed and supplied custom solutions which are aimed specifically at the data center sector and the fast-growing AI industry demands. Additionally, it has established a dedicated North America data center team to swiftly respond to growing demand in the U.S., and it has further invested in a global account team headquartered in Singapore to support key customers, ensuring proximity and ease of doing business.
Robinhood doubles revenue as it beats third-quarter earnings expectations CNBC
Robinhood profit skyrockets as retail traders ride market momentum MSN
A certain exchange’s Q3 net revenue reached $1.27 billion, exceeding market expectations. Bitget
Robinhood Markets Q3 Transaction-Based Options Revenue at $304 Million vs FactSet Analyst Consensus of $301.4 Million; Crypto Revenue at $268 Million vs Consensus of $310.3 Million MarketScreener
Acquired brain injury (ABI), either due to traumatic brain injury (TBI), neoplasm, encephalitis, or a myriad of other causes, is a condition with an impact on millions of individuals worldwide []. In many developed countries, there has been a surge in survival rates thanks to advances in acute care and neurosurgery []. These have not been mirrored by a corresponding enhancement in equitable access to quality care during the subacute and chronic phase postinjury [,]. Though survival may be improving, the burden of morbidity and disability continues to rise []. There is a wide range of potential complications from ABI, including pain, cognitive deficits, psychological distress, mobility, sensory, and balance issues []. Often, these issues are hard to screen for and manage in the acute setting []. Accessing appropriate care to identify, treat, and diagnose the complications of ABI can feel like an impossible task for individuals and their families []. Most health authorities lack an overarching strategy to address increasing demands, with limited services in hospitals or the community, threatening to overwhelm health systems [,].
With the advent and acceleration of digital technologies, health care professionals caring for individuals with ABI have an opportunity to use innovative techniques to assess, monitor, and manage complications []. The proliferation of mobile phone apps and the ubiquity of social media have made people with ABI and caregivers more connected than ever, even in the most remote environments []. Health professionals have also seen an enormous, if fragmentary, increase in digital tools in their practice, although most are not specific to ABI care []. Innovations in virtual reality (VR), augmented reality, wearable technology, and artificial intelligence have the potential to revolutionize the nature and administration of ABI and make it more equitable, effective, and personalized.
Research into digital technology in health care has accelerated in recent years, including in the area of ABI assessment, but there is little information on the breadth of research in this space []. It is vital to map the advances in ABI assessment to inform strategies for overall care, and reduce the burden on patients, families, and health services.
Objectives
This study aimed to identify and chart research on how digital innovations may assist with ABI assessment and symptom monitoring. The primary objective was to describe research in the use of ubiquitous “off-the-shelf” digital technologies (eg, smartphones, tablet computers, websites, VR platforms, and telemedicine platforms) to screen for, assess, and monitor the complications of ABI in the past decade. The secondary objective was to chart the predominant technologies being studied, how technology use has changed over time, the characteristics of the study participants, and the predominant study settings, methodologies, outcome measures, and findings.
Methods
Overview
This scoping review was conducted in accordance with the framework for scoping reviews outlined by Arksey and O’Malley [] and refined by Levac et al []. This structure was selected to facilitate a comprehensive and descriptive mapping of the rapidly evolving research landscape related to the use of digital technologies for clinical assessment in individuals with ABI. The framework outlines five key steps in developing and carrying out a scoping review: (1) identifying the research question; (2) identifying relevant studies; (3) developing criteria for appropriate study collection; (4) charting the data; and (5) collating, summarizing, and reporting the results, with or without expert consultation. An optional sixth step is the inclusion of an appraisal of quality, which may be appropriate depending on the research question. The review adhered to the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) checklist, which provides best practice advice for presenting the search strategy, findings, and implications [] (). This approach mirrors that taken in other scoping reviews on similar topics in depression, aging, and cancer rehabilitation [-].
Identifying the Research Question
The research question was developed by all authors through an iterative process. A preliminary search was carried out by the lead author on Medline to provide an approximate outline of the breadth and nature of studies on digital tools for ABI Assessment.
The overarching objective of the scoping review was to identify what English language studies exist from the past 10 years that evaluate the use of digital technologies to screen for an ABI, or assess for or monitor the complications of ABI.
We specifically evaluated:
1.1 The predominant technology platforms and apps being evaluated.
1.2 How the type and frequency of technology platform use changed over time, for example, smartphone/tablet, computer/web-based, or telemedicine platforms.
1.3 The predominant themes of ABI assessment for which tools were being developed to support, for example, cognitive assessment and physical examination.
1.4 The participant cohorts included, for example, demographic features, disease severity, and underlying etiology.
1.5 The characteristics of included studies, that is, what are the common themes in the studies’ aims, methodologies, outcome measurements, and main findings.
Identifying Relevant Studies
Prior to developing a search string, definitions for the key concepts of the study were agreed upon. ABI was defined as any individual who sustained an injury to the brain that was not developmental in nature or acquired at birth []. Due to the unique presentation and specific needs of individuals with stroke [], it was agreed not to include this cohort in the scoping review. Digital health technologies were defined in accordance with the US Food and Drug Administration as encompassing mobile health, health IT, wearable devices, telemedicine, and AI-assisted tools for health care assessment and monitoring []. Assessments were defined as any method to screen for, evaluate, quantify, or monitor ABI or its complications. The context was defined as any digital technology being used to aid assessment, monitoring, or screening tests on individuals with ABI in any health setting.
A systematic search strategy was developed a priori in consultation with a research librarian. The search was applied across MEDLINE (via Ovid), Embase (via Ovid), and Scopus. A comprehensive search string was developed by combining controlled vocabulary (eg, MeSH [Medical Subject Headings] terms) and free-text terms related to three core concepts: (1) ABI (eg, “acquired brain injury,” “traumatic brain injury,” “brain tumour,” and “encephalitis”), (2) digital technologies (eg, “telemedicine,” “mobile health,” “eHealth,” “apps,” “wearables,” and “artificial intelligence”), and (3) clinical processes (eg, “assessment,” “screening,” “monitoring,” and “measurement”). Boolean operators (“AND” and “OR”) and truncation were used to combine synonyms and refine results. Each database-specific syntax was adapted to its indexing system. The development process included iterative testing and refinement of the search terms and the review of reference lists of included studies to identify additional keywords. The full final search strategy for each database is available in [-].
A strategy for including gray literature was also confirmed A Priori. Scopus was used for its innovative feature that searches across multiple preprint databases, Embase’s feature for screening for conference abstracts was implemented, which was then used to search for full-text articles, both published and preprints. As well as research databases, 4 clinical trials registries were searched using broad search terms: the International Clinical Trials Registry, ClinicalTrials.gov, the European Union Clinical trials register, and the UK’s ISTRCN (originally called International Standard Randomized Controlled Trial Number).
Developing Criteria for Appropriate Sources of Evidence
The criteria for including articles in the process of charting and data mapping were decided by all authors following the preliminary search. We used a broad inclusion strategy to ensure the capture of exploratory, pilot, and feasibility work in addition to more established technologies and tools. Studies were deemed to be clinically relevant if they included individuals with ABI in their evaluations and included a description of the outcomes, regardless of the size of the study or the nature/quality of the study design.
The inclusion criteria were all studies that:
Were published in English (the language of the study authors).
Focused on digital health tools [,] for screening, evaluating, or monitoring ABI symptoms (either solely or as part of a larger patient cohort).
Reported primary research findings.
Were published between January 2013 and December 2024 inclusive. The decision to limit the search to this timeframe was informed by a preliminary search, which found that digital technologies predating 2013 were largely obsolete or incompatible with current digital platforms and clinical standards [,]. This approach has precedent in similar digital health scoping reviews [-].
The exclusion criteria were studies that:
Did not specifically address ABI or solely focus on participants with stroke.
Focused on nondigital methods of assessment without integrating digital tools, or when digital tools were not the focus of the evaluation.
Were narrative or systematic reviews, meta-analyses, editorials, or opinion pieces lacking original research data.
Were descriptive, protocols only.
Were still in development, that is, they did not involve assessment of real human participants with ABI.
Did not have accessible full texts.
Involved bespoke clinical devices that were not off-the-shelf or readily available digital technologies as defined by the US Food and Drug Administration and WHO guidelines on digital health and consumer-grade devices [,]. Examples of technologies and tools that do not fit these definitions could include digital intracranial pressure monitors, digital radiology devices such as MRI scanners, electroencephalograms, robotic gait aids, digital force plates, etc.
All articles captured in the systematic search were saved on a systematic review platform, Rayyan (Rayyan Systems Inc). The titles and abstracts of all articles were screened for relevancy by 2 authors working independently and blinded to each other’s decisions, with a third tie-break author included if needed. Following this, 2 authors reviewed all full-text articles for final inclusion based on prespecified criteria. Discrepancies were discussed and resolved through consensus; where consensus was not reached, a third author acted as an adjudicator.
Charting the Data
The Arksey and O’Malley framework [], and subsequent refinements by Levac et al [] and PRISMA-ScR [], recommend that a plan for the collection of data from included reports (ie, data charting), be developed and refined iteratively by the research team to ensure consistency and relevance to the research question. Using this approach, the research team carried out a preliminary search and identified the following key data elements to include: first author, year of publication, nature of the technology, target domain for assessment (eg, cognition, physical findings, and emotion/behavior), study aim, participant diagnosis and demographics, site and setting of the research, study methodology, primary outcome measures, and key findings including summary statistics. These data elements were agreed upon iteratively, following the preliminary and subsequent searches, to provide a comprehensive overview of the scope of research investigating digital technologies in ABI assessment, and to illustrate the breadth and variety of study design, setting, cohort characteristics, and quality. Data charting was completed by one author.
Collating, Summarizing, and Reporting the Results
Consistent with stage 5 of the Arksey and O’Malley framework [], and subsequent refinements [-], the charted data were collated, summarized, and reported using a combination of narrative description, descriptive numerical summary, and thematic analysis. The results were presented in narrative form, supported by a comprehensive data table providing a synthesis of setting and cohort characteristics.
A thematic analysis was developed iteratively by the study authors, where the type of clinical assessment served as the central organizing theme. Studies within these thematic domains were systematically compared by population, technology platform and specific app, study design, population, outcome measure, and findings—this was presented using a combination of narrative description and data tables.
Evaluation of Study Quality
The Arksey and O’Malley guidelines advise that a formal quality appraisal or risk of bias assessment is not typically required in scoping reviews, though subsequent refinements of the framework suggest that a quality appraisal may be considered in specific contexts such as when the goal is to inform clinical policy, or compare intervention effectiveness (though they highlight that formal tools, such as a risk of bias tool may not be useful if there is a broad variation in study designs included) [,]. Providing structured commentary on study quality can offer valuable context for interpreting findings and identifying directions for future research. Based on preliminary searches revealing substantial heterogeneity in study design, sample characteristics, and technological maturity, we determined that a formal risk of bias tool would not yield meaningful comparative insights. Instead, we included key indicators of methodological quality, including sample size, population features, use of comparators, randomization, outcome measurement, and tool validation in our data extraction table. This data was used to inform a structured narrative appraisal of strengths and limitations across the included studies.
Results
The Scope of Recent Evidence for Evaluating Digital Innovations in ABI Assessment
represents a PRISMA-ScR flowchart describing the results from the review and selection process. The search revealed 5293 unique articles, with 88 found to be relevant following the screening process.
Figure 1. PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) flowchart outlining the results from the review and selection process. * Excluded following title and abstract screening. **Excluded due to subject not fitting review criteria, that is, studies that do not evaluate the use of digital technology for clinical assessment. ***Excluded due to design or participants not fitting review criteria, that is, studies which do not include human participants with acquired brain injury, or review studies.
Technology Platforms and Apps
Most studies (n=45) focus on the use of smartphone (n=37) or tablet computer (n=8) based platforms for assessment of individuals with ABI. Most studies specified that they used a proprietary or commercial app to carry out assessments. Twenty-three studies describe computer-based (n=11) or web-based (n=12) tools; 11 studies used a telemedicine or teleconferencing platform; 9 studies used a VR platform, which included computer and VR eyewear. Five studies described using machine learning or artificial intelligence techniques alongside either a smartphone, tablet computer, computer, or web-based platform.
How Technology Platform Use Changed Over Time
presents the main technology platforms used from 2013 to 2024, with an increasing proportion of studies using smartphone or tablet-based tools over time.
Figure 2. Trends in technology platforms studied over time. VR: virtual reality.
Participant Characteristics and Setting
The median number of participants with ABI in each study was 25. There were 47 studies that included participants without an ABI; the median number of control participants in these studies was 50. Most studies included adult or late adolescent-adult participants and were not in a specific demographic group beyond their geographic area. summarizes the site, ABI cohort sizes, and setting of the included studies, as well as the number of studies that focused on specific subpopulations (ie, pediatric, athletic, or military). Regarding the etiologies for participants with ABI, 79.5% (n=70) of studies included TBI as the sole etiology, 18.2% (n=16) included a variety of etiologies including with TBI, encephalitis, ischemic stroke, hemorrhagic stroke, neoplasm, epilepsy or were unspecified; 2 studies included a single etiology, namely neoplastic disease [] and focal epilepsy []. A non-ABI cohort was included in 53.4% (n=47) of studies. This included 40 studies with healthy controls, 3 studies with participants with other morbidities (including orthopedic injury, pain, psychosis, or a history of trauma), and 4 studies that included both healthy and comorbid participants alongside participants with ABI.
Table 1. Setting and population characteristics.
Number of studies (n=88), n
References
Sites
Single site study
71
[,-]
Multisite study
5
[-]
Nationwide
9
[-]
Multinational
3
[,,]
ABIa cohort population size
<20
29
[,,,,,,,,,,,,,,,,,,-,,,,]
20-40
27
[,,,,,,,,,,,,,,,,,,-,,,,,,]
41-100
18
[,,,,,,,,,,,,,,,,,]
101-200
13
[,,,,,,,,,,,]
>200b
2
[,]
Specific populations
Pediatric
5
[,,,,]
Athletes/sports
11
[,,,,,,,,,,]
Military (soldiers or veterans)
7
[,,,,,,]
Setting
Laboratory or unspecified
24
[,,,,,,,,,,,,-,,,]
Community
37
[-,-,,,,,,,,,-,,,,-,,-,,]
Emergency department
5
[,,,,]
Inpatient
6
[,,,,,]
Outpatient clinic
16
[,,,,,,,-,,,,,,]
aABI: acquired brain injury.
b408 and 4999 participants, respectively.
Themes of ABI Assessment
Following data charting, the study authors identified 5 overarching themes, based on the type of clinical assessment that was being studied. These themes were as follows:
Screening for a diagnosis of TBI, either acute or historical.
Monitoring or evaluating common subjective symptoms of TBI, for example, headache symptoms, sleep issues, psychological symptoms, or a combination.
Objective assessment of cognition—either cognitive screening or more detailed cognition or memory testing.
Objective assessment of language or communication.
Clinical consultation—using technology as an aid to the entire process of assessment and treatment for an individual with ABI.
The following is a narrative synthesis of the included studies under each theme, including a description and comparison of the technology platforms used and specific apps leveraged for assessment, study design, population characteristics, outcome measures, and main findings. This synthesis provides an overview of the current quality of evidence and validity of findings. [-,-,-] is a data table organizing studies by theme, technology platform, and specific app, providing a comprehensive synthesis of study design, population characteristics, outcome measures, and main findings
TBI Detection or Screening
Fifteen studies focused on aiding the screening or diagnosis of a mild traumatic brain injury (mTBI) acutely [,,,,,,,,,], or screening for a distant history of TBI [,,,,].
Several novel techniques to aid acute mTBI screening were demonstrated, especially the analysis of voice and video captured parameters. Yadav et al [] carried out a large cohort study, recruiting from 47 high schools in the United States; they evaluated several machine learning techniques to analyze speech patterns in 95 participants at baseline and after mTBI, as well as a larger control cohort (n=486) and found the analysis software could be trained to be “reasonably” predictive of SRC (area under the curve=0.7). While the findings are promising, there was a lack of information on participant demographics, symptoms, and recovery, and we did not find further studies to validate these findings or address the real-world implementation of this tool []. The potential benefit of this approach is suggested by smaller studies of similar speech analysis tools, as well as studies combining speech and video analysis, and passive sensors of smartphone use [,,,,]. However, the quality of evidence remains limited as the study methodology and outcome measures varied widely. There is also little evidence on the implementation of these tools in a larger setting, alongside more established screening protocols or compared with surveys on symptom burden.
We identified 4 studies which evaluate adaptations of the Ohio State University Traumatic Brain Injury Identification Method designed to screen for a lifetime history of TBI. These adaptations, including web-based surveys, computer-assisted telephone interviews, consistently demonstrated feasibility and good test-retest reliability for assessing lifetime TBI history across diverse cohorts; however, there was some variation in how this tool was adapted for digital use, the populations studied, and outcome measures, somewhat limiting the validity of findings [,,,].
Symptom Assessment and Monitoring
Twenty-seven studies leveraged technology platforms to screen for, monitor, or quantify subjective symptoms related to TBI [,,-,-,,-,,,-,,,,,].
Many studies leveraged digital tools to monitor post-ABI symptoms and patient-reported outcomes [,,,,]. We found several investigations on the feasibility of web-based, or computer-adapted telephone and text-message-based surveys. Survey completion rate was mixed and tended to reduce over time. Karvandi et al [] provided serial surveys to 200 mTBI survivors and found <50% completion of all 3; however, importantly, the vast majority of respondents found the surveys to be useful. This was echoed by a small randomized trial by Suffoletto et al [], using daily text-message questionnaires as well as tips on self-management, and found no significant improvement in mood or anxiety outcomes but reported high patient satisfaction with the program. This may suggest that though engagement may be challenging, patients may perceive value in these methods of monitoring.
Ecological momentary assessment (EMA)—the real-time logging of symptoms and experiences in a patient’s natural environment []—was another area of extensive research. Two pilot RCTs of EMA-based interventions in TBI showed no significant differences in clinical outcomes compared with standard care, but did demonstrate high user engagement and satisfaction rates, similar to trials on survey implementation described above [,]. Our review found many small cohort studies investigating the feasibility of smartphone-based EMA apps prompting patients with ABI to report on sleep quality, pain, mood, or activity levels multiple times a day [,,,,] some of these investigations paired the EMA surveys with wearable sensors (such sleep and heart rate monitors), rate of compliance varied widely though it tended to be well regarded by participants. Several studies identified barriers to access, including cognitive impairments, health literacy, and memory deficits [,,]. Sherer et al [] outline several approaches to mitigate some of these barriers through regular phone calls to encourage engagement, and achieved a mean ≈80% response rate to EMA prompts. Overall, EMA was generally well tolerated, with many participants reporting it as useful, but there is a lack of evidence of its accuracy and impact on clinical outcomes across larger cohorts or longer periods.
Physical Examination
We identified 16 studies that leveraged digital tools to assist in the physical examination of individuals with complications of ABI [-,,,-,,,,,,], including the evaluation of gait, balance, motor power, vision, and visuospatial function. We identified nine studies that used smartphone or VR sensor data (accelerometers and gyroscopes) to evaluate balance, gait, or posture in patients with TBI, though most studies were in the pilot phase [-,,,,]—the only products evaluated in more than one study were Sway Balance (Sway Medical) and AccWalker (University of North Carolina). AccWalker was investigated in a cross-sectional study and found to be sensitive in identifying neuromotor changes postblast exposure in soldiers. In a later study, AccWalker was further evaluated among a cohort of soldiers and civilians exposed to mTBI versus controls. The vast array of sensor information was leveraged to identify a highly sensitive parameter for identifying concussion (variability of max velocity), evaluated among a cohort of 62 participants with mTBI and 154 healthy controls [,]. Sway Balance was also found to differentiate between athletes with mTBI and balance impairment versus controls [,]. The performance of these smartphone-based products has not yet been adequately validated, however, as the methodology, participant characteristics, and outcome measures of all studies were widely different. There remains a lack of validation among larger, more representative groups of TBI patients across multiple sites, nor efforts to replicate findings of pilot studies with standardized outcome measures.
Another area of interest is using smartphone technology to perform neurological pupil examinations. Four studies examined smartphone-based measurement of the pupillary light reflex (PLR) for TBI assessment. One large retrospective review (which included ≈28,000 ophthalmology outpatients) on the use of the BrightLamp app (Brightlamp, Inc) and reported a strong predictive value of a specific composite of PLR measures for mTBI, controlling for age and gender, though the assessors were not blinded to the diagnosis []. We identified reports of the smartphone pupillometry app PupilScreen (UbiComp Lab, University of Washington) studied prospectively in two settings (inpatient and ophthalmology OPD) [,], while another app, ReflexPro (Brightlamp, Inc), was also studied in laboratory setting, all consistently reported to be sensitive to PLR changes in TBI controls [], though they varied in terms of outcome measures and study design. These findings are promising, but further trials are needed to confirm the clinical impact of digital PLR tools, including in moderate-to-severe ABI, where they might serve as low-cost alternatives to specialized equipment in neurocritical care settings, especially in under-resourced regions []. There is limited but growing evidence that smartphone-based pupillometry may be comparable to dedicated pupillometry devices for a variety of ophthalmologic conditions, such as glaucoma [], as well as for monitoring sedation in the neurocritical care settings [,], though these applications also lack validation or rigorous meta-analysis.
Other areas of interest were in the evaluation of telemedicine facilitated clinical examination [,], as well as machine learning assisted video-based neurological examination of limb movement []. While promising, study cohorts were small, and we did not identify follow-up research to validate the findings or investigate their clinical application and implementation.
Cognitive Assessment
A variety of smartphone, computer-based, and VR tools were evaluated in 20 studies to help assess cognitive function in ABI [,,-,,-,,,-,,].
A number of relatively large studies demonstrated promising findings: Pellinen et al [] enrolled 408 individuals worldwide who were diagnosed with focal epilepsy to explore factors which impact completion of a web-based cognitive battery—they found male participants, and native English speakers to be more likely to engage whereas Black participants and participants with learning disabilities were less likely to engage—their work highlights barriers to receiving adequate clinical assessment and important areas to address as research moves towards implementation. The previously validated IMPACT screen for cognitive post TBI was adapted for tablet computer use [] as well as multiplatform web-based use [] and evaluated among 118-179 individuals with ABI and similar numbers age/gender matched of controls, both studies were sensitive in identifying cognitive changes in mTBI, though both were limited by narrow patient cohorts (trauma survivors and athletes respectively). Another tool which saw validation across 2 studies was the digital neuropsychological assessment, a web-based cognitive battery studied in TBI and control cohorts, with acceptable participant engagement, and significant cognitive differences between cohorts; however in a separate arm of one study, 30% of healthy participants scored in the 10th percentile for paper based tests, suggesting the reliability of digitally adapted assessments may be limited and requires careful evaluation [,]. Several smaller studies also evaluated adapted versions of cognitive assessments or a battery of tests for digital use; with most demonstrating feasibility and correlation with in-person or paper-based assessments, though with limited analysis of reliability of findings [,,,,].
We identified reports on the development and evaluation of a digital task or tasks in a virtual [,,,,,] or augmented reality [] environment, designed to test a range of cognitive domains and compared with healthy controls or benchmark paper-based tests. The largest “task-based” assessment included was described by Nadler et al [], who developed the “internet bill paying task,” a high-fidelity web-based task that accurately differentiated between mTBI and healthy controls in a nonrandomized cross-sectional study, it also correlated well with standardized measures of executive dysfunction and impaired verbal fluency, however this study and other task based assessments while promising, were not found to be validated beyond the findings of a single study and a single site and did not address potential barriers such as lack of digital skills or injury-related vision changes which may lead to spurious results.
Language or Communication Assessment
Four studies were identified evaluating the use of telemedicine to aid in assessment of ABI-related language or communication assessments [,,,]; this does not include several studies that assessed technology-based analysis of speech parameters to screen for acute mTBI, as discussed above. One small, randomized crossover trial, and one nonrandomized controlled study found that therapist-led evaluations of communication, using standardized tools over telemedicine platforms, yielded results comparable to in-person assessments carried out by separate assessors on the same individuals [,]. Telemedicine was found to be feasible and potentially effective for standardized assessment of discourse quality [,], for example, a trial by Turkstra et al [], identified strong concordance between in-person and telemedicine-based assessment of participant conversation, but highlighted that this was limited by small sample size (n=20) and that visual or cognitive issues may pose a barrier to engaging with telehealth assessments at a wider level. Like other assessment domains, the scope of evidence remains limited and disparate, with a need for further validation and studies on wider implementation.
Comprehensive Consultation
Three studies examined telehealth consultations for ABI patients in remote or underserved settings [,,] and while on study investigated the use of telehealth consultation to provide a rapid consultation service post mTBI for athletes []. The included studies were pilot, feasibility, and qualitative in design, with outcome measures centered on user-satisfaction, cost-effectiveness or feasibility; the efficacy of these technologies have yet to be evaluated in larger populations or across multiple sites. Several studies did indicate high levels of patient satisfaction with telehealth services, and significant estimated savings on travel costs [,]. Despite this, telehealth platforms often rely heavily on internet connectivity and patient familiarity with digital technology, none of the included studies evaluate the impact of potential barriers to access, such as individuals with limited digital literacy, or those whose symptoms may be exacerbated by screen use; nor do they address how these potential barriers may lead to a sampling bias [].
Discussion
Principal Findings
This scoping review identified a growing and diverse array of digital tools being used to screen, assess, and monitor complications of ABI across different populations and clinical settings. Advances in mobile apps, web platforms, telehealth, machine learning, and VR have enabled innovative approaches, with the most prominent themes found in the screening/identification of TBI, symptom assessment, physical examination, cognition and language assessment, as well as facilitation of a general consultation. While some digital assessment apps show promising preliminary evidence, many areas remain understudied, and the tools included lacked standardization across studies. The goal of this scoping review was to provide a comprehensive overview and synthesis of recent research, which included details on study characteristics without a formal assessment of quality; therefore, it provides limited insight into the efficacy of specific platforms or tools, or how they may serve a wider population. For all the themes identified, future work should focus on validation of findings, approach questions of implementation and scalability in real-world settings, and address ethical concerns such as barriers to access and data privacy.
Gaps and Limitations in Current Evidence
Although this review mapped a broad range of digital innovations, the overall evidence base has significant limitations. The studies were highly heterogeneous in terms of participant populations, technology types, and outcome measures. Most involved small, or specific cohorts (eg, exclusively athletes or military personnel), which limits generalizability. Few technologies were evaluated in more than one study or site. Notable exceptions involved the Ohio State University Traumatic Brain Injury Identification Method survey and several balance assessment apps, each examined in at least two studies; however, methods and outcome measures varied between those studies. As a result, most digital tools identified in this review lack robust validation across diverse clinical settings. Rigorous study designs were also scarce: we found five randomized controlled trials in total (all of them small feasibility studies), while the majority of studies were observational and many lacked control groups. These weaknesses mean the effectiveness and clinical utility of many digital assessment tools remain unconfirmed. This issue is not unique to ABI, with similar limitations identified in other scoping reviews of digital health across domains of depression, cancer rehabilitation, and aging [-].
Barriers to Implementation and Stakeholder Engagement
The development and implementation of digital tools also remains ad-hoc, with almost no reference to implementation strategy or the involvement of stakeholders in co-design, key features to maximize the utility and acceptance of an innovative tool []. There has been growing acceptance of application theory across other areas of ABI research, including in education campaigns and new rehabilitation strategies []. These frameworks should help guide the wider introduction of potentially useful tools.
Ethical, Accessibility, and Data Security Considerations
Discussion on potential risks, ethical concerns, and data security was limited. Several studies explicitly addressed local data protection law compliance [,], or the use of an encrypted server or database [,,,,], though the majority did not present detailed information on the exact data privacy and security protocols. Another area that is important to address is accessibility, while technology does have the potential to improve access, potential barriers to access, such as visual/hearing impairments, poor health literacy, or lack of internet access, were rarely addressed or actively mitigated []. Most developed countries have detailed data privacy and security laws, such as the Health Insurance Portability and Accountability Act and General Data Protection Regulation in the United States and the European Union, respectively []. It is vital that strict adherence to these laws is demonstrated as a minimum standard as research continues to grow. International bodies such as the WHO have developed guidelines on the safe integration and evaluation of digital health technologies across health services []. These can serve as a framework for safe, ethical, and just implementation strategies for promising technologies in the future.
Priorities for Future Research
Larger, more rigorous studies (ideally across multiple centers and in real-world clinical settings) are needed to confirm the reliability and effectiveness of these digital tools. Validation is especially important when the digital tool is involved in making a “diagnosis” such as in mTBI screening or cognitive assessment—though many studies showed promise in aiding these diagnoses, inaccurate findings could lead to misdiagnosis and significant harms; a key focus should be on ensuring a standardized approach to evaluating digital tools: with studies that include similar cohorts, experimental designs and outcome measures. More evidence is required on how access to innovative tools may impact overall recovery; this will again require studies with much larger cohorts and longer follow-up times. We need to better understand how to implement these tools across the scope of care and ensure adequate penetrance when a tool is effective, adherence to implementation strategies [], not just identifying barriers to access but actively mitigating them [,]. More work is also needed to provide better assessment and monitoring in all cases of ABI (not just mTBI or specific populations such as athletes), and for complications such as seizures, behavioral symptoms, and participation restrictions.
Conclusions
This review highlights major strides in the application of technology to help improve how individuals with ABI are screened and assessed. There is a particular focus on mTBI, with less published on assessments of patients with moderate to severe TBI, or other aetiologies of ABI. Most studies performed to date include small numbers of patients, designed as pilot or feasibility studies; thus, more rigorous research is needed to better understand the efficacy and applicability of various technologies. Future developments should also consider the assessment of less-explored complications of ABI, and leverage assessments across multiple domains to provide holistic care. It is important to ensure that this work considers the ethical implications of the technologies involved, including issues such as accessibility, digital literacy, privacy, and security.
Though this synthesis can help guide research in promising areas, or where there are gaps, more steps are needed to help guide the implementation of a specific innovation or policy, such as a systematic review with a more narrow focus and a formal risk of bias tool.
This review should inform the development of further digital tools to provide a comprehensive and equitable approach to clinical assessment in patients with ABI, which is accessible and efficacious for all.
Access to MEDLINE, Embase, and Scopus was available to authors through affiliations with University College Dublin and the University of Calgary.
CO (first author) completed preliminary search, screening, data charting, and synthesis; drafted and proofread the manuscript; and codeveloped the review protocol. AM (second author) completed screening and proofreading and codeveloped the review protocol. GM (third author) served as the academic librarian, developed the search strategy, and codeveloped the review protocol. CD (supervising author) completed the screening (tie-break author), proofread the manuscript, and codeveloped the review protocol.
None declared.
Edited by A Schwartz, T de Azevedo Cardoso; submitted 02.Mar.2025; peer-reviewed by T Adebambo, C Onah, A Adeoye; comments to author 02.Apr.2025; revised version received 28.May.2025; accepted 08.Sep.2025; published 05.Nov.2025.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
DoorDash shares slid as much as 19 per cent after hours on Wednesday following weaker than expected third-quarter profits and big increases to its spending plan on tech upgrades next year.
The food and grocery delivery app said it generated net income of $244mn in the third quarter, below expectations of $295mn, according to forecasts compiled by Visible Alpha.
Its financial outlook for the fourth quarter was also lower than expected. DoorDash said it planned to spend “several hundred million dollars” more next year than it did in 2025 on initiatives including a new technology platform for its global brands Wolt and Deliveroo.
Profits fell short despite the value of orders placed on the platform growing 25 per cent year on year to $25bn, ahead of estimates of $24.6bn.
DoorDash, which operates in more than 40 countries, said it experienced strong growth in monthly active users, adding nearly twice as many customers in the US in 2025 as last year.
It said growth and investment in its tech would come at the expense of short-term costs.
“We wish there was a way to grow a baby into an adult without investment, or to see the baby grow into an adult overnight, but we do not believe this is how life or business works,” DoorDash said in its earnings release.
The company said the UK’s Deliveroo, which it acquired this year for £2.9bn, would contribute roughly $45mn in adjusted earnings before interest, taxation, depreciation and amortisation in the fourth quarter. It expects the platform will contribute about $200mn in the coming year.
DoorDash said Deliveroo’s contribution for next year was $32mn to $40mn lower than prior estimates, after “aligning our accounting treatment and definitions”.
Long Beach, Calif. November 5, 2025: Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today successfully launched its 74th Electron mission and deployed the latest satellite to orbit for Institute for Q-shu Pioneers of Space, Inc. (iQPS). The mission was Rocket Lab’s sixth dedicated mission for iQPS, making Rocket Lab the most prolific launcher of their Earth-imaging constellation to date.
‘The Nation God Navigates’ mission lifted off from Rocket Lab Launch Complex 1 in New Zealand at 19:51 UTC on November 5th to deploy a single synthetic aperture radar (SAR) imaging satellite named QPS-SAR-14 (nicknamed YACHIHOKO-I for the Japanese god of nation-building) to a 575km circular Earth orbit. Electron will launch six more dedicated iQPS missions following the recent signing of an additional multi-launch agreement to build out their constellation in low Earth orbit.
Rocket Lab founder and CEO, Sir Peter Beck, says: “Success in the space industry boils down to precision and repeatability. This latest mission for iQPS once again demonstrates the pinpoint accuracy our customers depend on to grow their constellations, and we’re grateful to the iQPS team for trusting us with their launch needs. With six seamless deployments for iQPS in the books, Electron is ready for the next six.”
iQPS CEO, Dr. Shunsuke Onishi, says: “We are pleased to announce the successful deployment of QPS-SAR-14 ‘YACHIHOKO-I’, marking our fifth successful launch this year. This milestone reflects the steady advancement of our technology and the growth of our team. We sincerely thank the Electron team and all our members for their outstanding work. With this success, we move closer to realizing our vision of near real-time Earth observation and delivering greater value to society.”
‘The Nation God Navigates’ was Electron’s 74th launch to date and 16th this year, meeting Rocket Lab’s current record high of yearly launches, which was 16 in 2024. With more Electron missions scheduled throughout the remainder of 2025, Rocket Lab is on track for another record-breaking year of launches, all while the Company prepares for the debut launch of its medium-lift reusable rocket, Neutron.
Launch images: F74 | The Nation God Navigates | Flickr
Rocket Lab Media Contact Kate Gamble media@rocketlabusa.com
About Rocket Lab Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier, and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle, a family of spacecraft platforms, and the Company is developing the large Neutron launch vehicle for constellation deployment. Since its first orbital launch in January 2018, Rocket Lab’s Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered over 200 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab’s spacecraft platforms have been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch pad in Virginia.
Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our launch and space systems operations, launch schedule and window, safe and repeatable access to space, Neutron development, operational expansion and business strategy are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “strategy,” “future,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to the factors, risks and uncertainties included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of our website at www.rocketlabusa.com, which could cause our actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Smoking causes severe health consequences, and there is no safe level of secondhand smoke (SHS) exposure [,]. SHS exposure among children increases the risk of sudden infant death syndrome, chronic respiratory diseases such as asthma, and lung cancer in adulthood []. Over 40% of children in the United States are regularly exposed to SHS, most often by a parent []. When a parent quits smoking, they significantly lower their chances of developing lung and other related cancers and lengthen their life expectancy []. Parental smoking cessation eliminates the majority of children’s SHS exposure and decreases the odds that their children will become tobacco users themselves [-]. Pediatricians are well positioned to help parents quit smoking by implementing interventions that connect parents with cost-effective, evidence-based tobacco cessation treatments [,]. Furthermore, for low-income households, where the smoking rate can be 2 times the general population level, pediatricians are often parents’ primary source of interaction with the health care system [,]. Thus, integrating tobacco cessation treatment within pediatric care holds great promise for mitigating the harm of tobacco within families.
While pediatric health care systems are uniquely positioned to help parents and household members (henceforth referred to as parents) quit smoking, evidence-based treatments are significantly underused []. Cost-effective cessation strategies exist, especially when behavioral and pharmacological interventions are combined (eg, nicotine replacement therapy [NRT] plus the Quitline) []. Compared to controls, behavioral interventions, such as telephone- or text-messaging–based counseling, and NRTs significantly increase smoking cessation rates and can easily be disseminated [,]. The 2021 US Preventive Services Task Force, Healthy People 2030, the Department of Health and Human Services, and the surgeon general all strongly recommend that clinicians ask all adults about tobacco use and provide behavioral interventions and pharmacotherapy for cessation [,-]. To best address tobacco use among parents, it is ideal to develop scalable solutions that are coordinated across health systems, community partners, and national services.
Fortunately, advances in health interoperability standards, such as Fast Healthcare Interoperability Resources (FHIR), SMART on FHIR (hereafter referred to as SMART), and CDS Hooks, have created opportunities to more easily support these efforts [-]. FHIR is a health information exchange standard that allows clients (eg, clinical decision support [CDS] services) to obtain granular access to data, such as encounters, allergies, or medications, using a standardized application programming interface (API). SMART is a standard that allows authorized apps to be opened directly from an electronic health record (EHR) or patient portal so that clinicians and patients can seamlessly access external apps within their workflow. CDS Hooks is an event-driven framework in which specific actions in the clinical workflow, such as ordering a medication and trigger messages, known as “hooks,” are sent to subscribing services. These systems can then return recommendations as a “card” to the user directly within their EHR workflow. Systems built on these standards, known as service-oriented systems, are separate from the host system (eg, EHR) but connected using a standard API []. This allows for a modular, scalable approach that can extend care beyond the individual patient.
Several researchers have already begun to explore using these standards for developing CDS systems. Investigators in one health system demonstrated the utility of the SMART framework within the EHR using both clinician- and patient-facing apps to address clinical needs such as patient-specific medication instructions []. Dolin et al [] developed a prototype pharmacogenomics CDS service that interfaced with a commercial EHR using the CDS Hooks standard, and Jung et al [] used CDS Hooks to implement a national service for drug allergy interaction checking. Other researchers have sought to combine standards within the same system. Theiss et al [] developed a prototype app that combined several health information technology standards in a nonproduction setting, and Morgan et al [] combined contextual CDS Hooks prompts to direct clinicians to SMART apps within their hospital’s emergency department.
These studies highlighted the utility of each standard; however, the apps were designed mainly to support clinicians, not patients or families, and were deployed in nonpediatric settings. Lastly, while some use cases have connected to external systems (eg, Value Set Authority Center or RXNorm) to retrieve information, the apps did not interface with community health care partners. In this viewpoint, we describe our experience in developing and implementing a parent tobacco treatment platform (PTTP) within a pediatric institution that leverages multiple international standards to support interoperability, with the overarching goal of providing a model for how such work can be approached. We highlight three key areas where critical decisions shaped the design and trajectory of the system: (1) international standards, (2) community partnerships, and (3) family-centered care. By sharing these lessons, we aim to guide other health IT developers, physicians, health care leadership, and standards development organizations in designing, implementing, and scaling CDS interventions.
How We Designed the PTTP
Project Setting
The PTTP was developed as part of a National Institutes of Health funded research initiative focused on connecting the parents (including caregivers and other household members) of our patients with smoking cessation services within the Children’s Hospital of Philadelphia (CHOP) Care Network and Pediatric Research Consortium [], which includes a combination of suburban, urban, and semirural practices that use a common EHR (Epic Systems Inc). The tool was initially deployed in 5 clinics and has since expanded across all CHOP’s primary care and pulmonary medicine networks (35 sites). Development (including user analysis and design) of the CDS system occurred between January 2020 and November 2023. To support this work, a multidisciplinary team was formed that consisted of physicians, a software engineer and EHR-integration expert, a human-computer interaction specialist, and project managers. The project was approved by the CHOP Institutional Review Board (IRB 20‐018146).
System Overview
On the basis of a rigorous human-centered design evaluation, which consisted of interviews with clinicians, parents, and front-desk staff, formative testing of prototypes, and iterative feedback sessions, we identified that the system needed to support 2 high-level workflows () [,].
Figure 1. Conceptual framework for connecting parents to tobacco cessation treatment from the pediatric chart. EHR: electronic health record.
First, the system needed to screen, identify, and automatically connect parents to the requested treatment options. Although some health care providers (HCP) already routinely ask parents about their smoking status, our team found that the process is inconsistent. Furthermore, parents felt more comfortable disclosing their smoking status through a survey that used nonjudgmental language []. Additionally, to engage parents during a potential activation window, where they are energized to engage in treatment, all treatment connections needed to be processed immediately upon user responses. From these priorities, we hypothesized that an event-driven architecture, responding to previsit questionnaires in the patient portal, would meet the needs of our project. This architecture includes the following high-level layers: (1) producer (source of events), (2) broker (sender of events), and (3) subscriber (listener of events; ) []. Questionnaires can be completed up to 7 days ahead of the visit within the patient’s personal health portal (MyChart; Epic System), during check-in, or by the HCP during the visit. The questionnaire is configurable within our vendor EHR and includes questions about smoking use; if the respondent indicates that they smoke, it provides a motivational message to encourage treatment engagement and three evidence-based treatment options: (1) NRT, (2) Quitline enrollment, and (3) SmokefreeTXT enrollment. The Quitline is a free, state-specific, telephone-based smoking cessation service that provides counseling, referrals to other programs, and access to free medication. SmokefreeTXT is a free mobile text messaging service offered by the National Cancer Institute that provides daily tips and 24-hour support for quitting smoking. Treatment connections are processed immediately upon completion of the questionnaire.
Figure 2. Event-driven architecture.
Second, the system should incorporate a component embedded within the clinician workflow in the EHR. HCPs were interested in understanding the smoking status of the household, given its impact on the child. To reduce the burden on HCPs, who have to juggle many competing priorities in a limited amount of time, the clinician-facing component needed to not only summarize smoking use in the household but also quickly allow HCPs to connect parents to smoking cessation treatment and support other clinical tasks within the EHR, such as documentation and billing. We hypothesized that a client-side rendering architecture would serve the needs of this component []. This architecture includes the following layers: (1) presentation (eg, the user-facing app), (2) application (eg, clinical logic), (3) service (eg, connection to database and treatment partners), and (4) database (storage of app data; ).
We mapped the architectural needs of our system to interoperability standards across all versions supported by Health Level 7 (HL7) International (draft standard for trial use, standard for trial use, and release). To reduce potential dissemination barriers of our system to other organizations, we prioritized standards based on modern internet protocols (eg, FHIR) and limited them to only those well supported by our commercial EHR vendor. Refer to for the list of standards that were evaluated.
Table 1. Interoperability standards reviewed.
Standard
Description
Component
CDS Hooks []
An event-driven architecture, where events in the EHR (known as hooks) trigger messages to subscribers. Currently an HL7 standard for trial use, it uses FHIR for the data model standard, and OAuth 2.0 and OpenID Connect for authorization and authentication.
Parent
Direct messaging []
Method of securely exchanging information to trusted partners. Commonly used with Simple Mail Transfer Protocol and the Continuity of Care Document as a method for exchanging clinical information. Used by some EHRs to connect patients to telephone-based counseling services.
Parent
Clinical Quality Language []
A standard for representing clinical logic to enable sharing across institutions. The language is both human- and machine-readable, and common use cases include quality measures and decision support.
Parent and clinician
FHIR []
Health information exchange standard that takes advantage of popular internet protocols and data formats. Increasing in popularity among health care developers and now on release 6.
Parent and clinician
SMART []
Standard to integrate external apps into health information systems such as the EHR. Uses OAuth 2.0 and OpenID Connect for authorization and authentication and FHIR for information exchange standard.
Clinician
Web messaging []
HL7 standard for supporting tighter integration between the host system and embedded SMART app. Relies on HTML5’s web-messaging protocol to support communication between systems. While not directly supported in our EHR, our EHR vendor provides a similar web-messaging framework, which is included as part of our evaluation.
Clinician
aEHR: electronic health record.
bHL7: Health Level 7.
cFHIR: Fast Healthcare Interoperability Resources.
While HL7 version 2 messaging is the most common event-driven standard used in health care, its implementation often uses a transmission control protocol, which is at a lower level of the Open Systems Interconnection model compared to more modern standards, such as FHIR []. As a result, it is generally not a preferred health information exchange standard for new developments. Evaluations occurred at the following technology layers, where standards were available: (1) EHR-integration framework (eg, SMART, CDS Hooks, and web messaging), (2) data model (eg, FHIR), (3) logic (eg, clinical quality language [CQL]), and (4) community information exchange (eg, direct).
Interoperability Standards Selection
The smoking cessation system () has 2 high-level components, a parent-facing and a clinician-facing system, with services shared between them (). Both components are described below, with a separate section dedicated to shared services. provides an overview of the use of standards across each component.
Not available; used vendor provided web-messaging framework
Vendor
Documentation templates
Used to automate clinical documentation
Order sets
Used to automate clinical documentation
Web messaging
Used to “listen” to clinical events, such as when a patient’s problem list was updated
Patient
Standards
CDS Hooks
Partially used; required enhanced trigger set provided by our vendor EHR
FHIR
Used per specification
CQL
Not used
Vendor
Alert framework
Extends the “hooks” available as part of CDS Hooks specification
aFHIR: Fast Healthcare Interoperability Resources.
bEHR: electronic health record.
cCQL: clinical quality language.
Patient-Facing Component
We first evaluated technologies that would meet the needs of the parent-facing CDS, which was delivered through a previsit questionnaire. Given the existing support for the direct messaging protocol within our EHR and the Pennsylvania Quitline, we initially attempted to facilitate connections using this method. However, as CHOP is a pediatric hospital and does not maintain charts for adults, the Direct protocol did not readily support transmitting information about the parent through the child’s chart. Additionally, other treatment partners did not support the direct protocol. Therefore, a separate service was required to create a connection between the parent and our community treatment partners.
We then evaluated the CDS Hooks standard. While CDS Hooks services are traditionally used to deliver information (eg, recommendations) in the form of a card within a user’s (eg, clinician) workflow, we were interested in using the standard to perform asynchronous tasks. Unfortunately, the current version of the standard does not support a hook based on the completion of a questionnaire. However, our EHR’s implementation of CDS Hooks provides a richer set of triggers, including the completion of a previsit questionnaire. While the use of widely available standards was preferred, other options would have required significant customization and project-specific code. As a result of this and early demonstrations related to adding a hook for responding to patient-completed questionnaires [], we chose to move forward with the CDS Hooks. Immediately after submitting the questionnaire, a Patient_View hook is immediately triggered from the EHR to our system. The system authenticates the message, evaluates questionnaire responses retrieved via FHIR, and connects parents to the requested treatment options.
After determining the trigger mechanism, we explored CQL as a standards-based method for evaluating the patient’s data to determine whether treatment options were requested. While the CQL rule performed as expected, part of the EHR configuration required to send a CDS Hooks message after completion of a previsit questionnaire included a native EHR rule, which already evaluated questionnaire responses. Given this and the additional infrastructure required to support the CQL standard, such as the rules engine, which is not readily supported by our EHR, the CQL rule was considered redundant and removed. In its place, a combination of EHR-based rules within the questionnaire configuration and logic statements in the CDS Hooks service was used.
Clinician-Facing Component
Next, we evaluated standards-based methods for developing and implementing the clinician-facing component. Given the recent federal regulation mandating support for SMART [], we chose this method to embed this component directly within the HCP’s EHR workflow, requiring no additional clicks to navigate to or open. The app was written in React (JavaScript) and supports multiple HCP tasks within the EHR. For parents who smoke but do not select a treatment during the questionnaire, the app allows HCPs to enroll the parent in treatment if they change their mind. The system also allows HCPs to add SHS to the problem list with a single click and includes a section with prompts on how to discuss tobacco use with parents and treatment information. Furthermore, the app automates several routine tasks, including populating text within the encounter note and after-visit summary and defaulting visit diagnoses in order sets. When a parent accepts treatment and counseling is performed by the HCP, the system also provides information on how to appropriately bill for the visit.
To facilitate a tight integration between the app and the EHR, we took advantage of our EHR vendor’s web-messaging framework that enables navigation to different areas of the chart, such as viewing questionnaire responses. Although similar to SMART Web Messaging, our EHR’s framework also allows embedded apps to “listen” to events originating from the EHR, such as when a patient’s medications or problem list are updated. For example, to ensure that SHS is not added to the patient’s chart multiple times, our system listens for changes to the patient’s problem list and updates itself accordingly.
Community Partner Connections
Both the parent- and clinician-facing components use a set of shared services to connect parents to smoking cessation treatment. At the time of our project, limited options existed to support information exchange between the EHR and community partners. Unfortunately, due to varying technical resources across our treatment partners, as well as the lack of support for family-centered care within our EHR, standards-based methods for connecting parents from the child’s chart were not possible. As a result, a separate service was required to connect parents to each partner, as detailed in the subsequent sections. All services are secured using the OAuth 2.0 token infrastructure.
NRT Treatment
Since the smoking cessation system was embedded within the child’s chart, traditional methods to prescribe medication (eg, E-Prescribe) were not available. To connect parents to NRT, we contracted a third-party pharmacy that delivered medication to the parents’ homes. However, as a smaller organization, the pharmacy lacked the resources to develop a process for ingesting parent information using more modern techniques, such as an API. Consequently, we developed a service to send parent information and a system-generated PDF of a prescription using encrypted email.
Text Message–Based Counseling
We partnered with SmokefreeTXT to provide text-based counseling to parents. SmokefreeTXT is a text message program provided by the National Cancer Institute that provides a web form that individuals can complete to enroll []. We initially attempted to integrate this web form directly into our previsit questionnaire, but due to network restrictions within our organization, this was not possible. Additionally, because the questionnaire includes other treatment options beyond SmokefreeTXT, the use of the web form may have required users to enter their information multiple times if they were interested in other treatment options. At the time of our project, no automated mechanism existed to connect individuals to the program, so we engaged directly with the SmokefreeTXT operating partner to request the development of an API. The API initially only accepted the participant’s phone number; however, a primary goal of our project was to remove as many potential barriers to treatment engagement as possible. As a result, to streamline the enrollment process, which required the user to respond with additional information after enrolling (eg, target quit date and current age), a second API was enabled to programmatically update these values, using information already provided in the questionnaire.
Telephone-Based Counseling
Because CHOP provides care across multiple states, we needed to partner with 2 separate telephone counseling organizations in Pennsylvania and New Jersey, each with different connection requirements. Quitline selection is determined by the location of the participating clinic. The Pennsylvania Quitline supports the use of the Direct Messaging protocol. Unfortunately, as mentioned above, Direct Messaging does not account for the family-centered nature of care and can only readily be used if the connection originates from the patient’s chart. In an attempt to establish real-time connections, we evaluated the development of an API similar to that used for SmokefreeTXT; however, this was not possible at the time due to limited resources. Additionally, the Pennsylvania Quitline had already established a robust infrastructure where enrollments are processed through a daily file exchange using the Secure File Transfer Protocol. To build the file, a script queries our clinical data warehouse to identify the participants who are requested to be enrolled. This file is then retrieved by the Quitline partner, who is given remote access to the directory, and processed by their system. For our New Jersey partner, due to resource constraints, connections are sent using encrypted email in a process similar to that of our pharmacy partner (described above).
Impact on Family-Centered Care
Parents want their child’s physician to discuss smoking cessation treatment with them []. However, in pediatric settings, appropriate tobacco treatments are rarely, if ever, provided to parents who smoke []. This is largely due to workflow limitations in the pediatric EHR, especially the inability to account for the family aspect of child health care [,]. EHR vendors often develop features for the physician-adult patient dyad. However, as noted above, they provide limited support to connect family relationships, making it challenging to leverage existing technologies to support teamwork across the patient’s entire network (eg, care team and community groups), particularly in pediatric settings [].
Our system focused directly on the family-centered nature of a child’s care. Therefore, over a 1-year period, our system was used in 194,946 visits and identified 7847 (4.03%) parents who smoked. Of those who smoked, 37.64% (n=2954) selected at least one treatment option, 29.27% (n=2297) selected NRT, 29.46% (n=2312) selected SmokefreeTXT, and 21.8% (n=1711) selected the Quitline (). Performance of the app was excellent, with 99% of all treatment connections handled through the previsit questionnaire and CDS Hooks service without clinician involvement. The remaining 1% of the connections were facilitated using the clinician-facing tool. Interaction (eg, clicks) within the clinician-facing system was limited, occurring in only 774 (<1%) encounters. Given the low level of interaction with the system by HCPs, routine check-ins with practice management were established to ensure that any issues with usability were identified and corrected. No issues were identified during the project period. The uptime of the system (across all components) was 99.99%, with most outages related to network faults that occurred for less than 1 minute. We identified multiple failures in the web-messaging framework; however, these only limited navigation to different areas of the chart from within the app (eg, viewing the questionnaire) and did not impact parent connections. The median (IQR) response time across all system services was 60 (14,393) milliseconds.
Table 3. Questionnaire completion and treatment connection rates.
Metric
Count, n (%)
Questionnaires assigned
267,282 (100)
Questionnaires completed
194,946 (73)
Patient portal
99,063 (51)
Visit check-in kiosk or tablet
94,561 (49)
During visit by clinician
1322 (<1)
Identified person who smokes
7847 (4)
Patient portal
2946 (38)
Visit check-in kiosk or tablet
4836 (62)
During visit by clinician
65 (<1)
Treatment connection
Any
2954 (38)
NRT
2297 (29)
SmokefreeTXT
2312 (29)
Quitline
1711 (22)
aNRT: nicotine replacement therapy.
Discussion and Future Directions
By combining multiple international health data standards and reusing app services across system components (parent and clinician facing), we were able to develop the EHR-integrated PTTP. Our system connected parents (including caregivers and other household members) with smoking cessation treatment at scale, serving hundreds of thousands of families across a diverse patient and practice population. This represents a significant increase compared to prior work [-]. Furthermore, by developing our system in a modular way, we helped to lower the barriers to implementation in another health system on the same EHR, which is using components of our platform []. However, our work also showed that there are limits to using international interoperability standards to support family-centered care in pediatrics.
First, some standards, such as CDS Hooks, are limited in scope and support only a fraction of the potentially actionable events that occur within a health care system. Engaging with patients and families outside of the clinical encounter is a growing area of interest in the health care community []. One method of doing this is through previsit questionnaires, which can be completed in the patient’s health portal. Using our EHR vendor’s enhanced set of CDS Hooks triggers, our system was able to immediately respond to parents completing a previsit questionnaire. Compared to adult settings, where only 7.6% of patients received a medication associated with tobacco use treatment [], our system connected 29% of the parents. Additionally, 99% of these connections occurred automatically, without requiring any work from the visit HCP. While CDS Hooks was originally intended to support more synchronous workflows, such as validating orders at the time of ordering, our team envisions a much larger role for the standard to support asynchronous workflows that do not require input from the health team. This could help organizations across EHR platforms change how they engage with their patients and even alter the dynamics of an individual visit.
Additionally, variability in health care workflows and implementation of standards across EHR vendors creates a need to adapt even standards-adherent systems for implementation in different health systems [,,]. This is especially true for standards that are flexible to institutional workflows, such as SMART, which, depending on the EHR, can integrate into the EHR at different stages of the visit or locations in the chart. Furthermore, health care is a complex adaptive system, and a single workflow may not work across organizations []. Therefore, even for EHRs that support SMART, individual implementations may differ across care domains (eg, inpatient vs primary care) or organizations. Given these limitations, future research and implementation efforts should evaluate whether a combination of standards-based and native EHR technologies would increase portability while reducing maintenance.
Second, standards are not widely adopted outside of health care organizations, such as hospitals or clinics. Recent regulations require EHR vendors to support health interoperability technologies for certification with the Office of the National Coordinator for Health Information Technology []. However, smaller, health care–adjacent organizations similar to our community partners may not use commercial EHRs and often lack the resources to support integrations using international standards. Additionally, standards supporting EHR integration with community partners, such as the Direct protocol, do not support connections for others within the patient’s network (eg, parents). As a result, our system needed to support 3 different methods of information exchange (eg, encrypted email, API, and secure file transfer protocol), and even those that shared a protocol required different information within the message. To fully realize the potential of our system to support interoperability at the community partner level, additional work is needed to create a standardized method for exchanging information. One promising standard-based method to support this is the FHIR ServiceRequest profile, which has been part of the United States Core Interoperability implementation guide since version 2 was released in April 2022.
Lastly, our work showed that the concept of the EHR as a hub, where the EHR provides the necessary capabilities to support teamwork across the patient’s entire network (eg, care team and community groups), is not well supported, particularly in pediatrics []. For example, if a parent has 2 children, ideally, our system would only request information (via the previsit questionnaire) once. However, as patient records rarely contain family-based associations [], the parent is presented with the questionnaire multiple times, which may result in parental frustration and potentially conflicting information across their children’s charts.
Performance of the PTTP was acceptable, with near-perfect uptime across all components. However, we identified issues that warranted attention, including network failures and communication with our EHR’s web-messaging framework. While a growing body of work has identified how CDS can fail, the focus has largely been on centralized computing models where the data and the computation are on the same machine [-]. Architectures taking advantage of newer HL7 standards create new complexities and failure modes that are not recognized with existing frameworks []. To ensure the ongoing safety and effectiveness of service-oriented CDS, more research into these failure modes is necessary.
Conclusions
We found that it is feasible to develop and integrate CDS using a hybrid architecture that combines several health IT standards such as SMART, FHIR, and CDS Hooks. These types of systems are likely to increase over time; however, additional work is necessary to both expand existing standards to integrate with the EHR and streamline information exchange processes for sharing data, when appropriate, with third-party systems about a patient’s care network (eg, parents) whose behaviors impact the patient. Similarly, improved EHR support for linking patient records of family relationships will help to align health data across families.
JGT, BPJ, AGF, and RWG contributed to the research design, data acquisition and analysis, and manuscript preparation. JED, EN-B, and JPW contributed to the research design and manuscript preparation. DK, JR, SK, and EN contributed to the acquisition and analysis of the data and manuscript preparation. All authors approved the final manuscript as submitted.
None declared.
Edited by Naomi Cahill; submitted 29.Mar.2025; peer-reviewed by Sonish Sivarajkumar, Vidhya Prakash; accepted 14.Oct.2025; published 05.Nov.2025.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.
New Brunswick, N.J., November 5th, 2025 – Johnson & Johnson (NYSE: JNJ) will present at the Citi’s 2025 Global Healthcare Conference on Wednesday, December 3rd, 2025. Management will participate in a Fireside Chat at 11:15 a.m. Eastern Time.
A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day.
The audio webcast replay will be available approximately 48 hours after the webcast.
Hyatt and Chase Expand their Collaboration as World of Hyatt Loyalty Program Continues Industry-Leading Growth
World of Hyatt reaches more than 60 million members, growing at a rate of nearly 30% annually since 2017
CHICAGO, IL (November 5, 2025) – Hyatt Hotels Corporation (the “Company”) (NYSE: H) today announced an expanded agreement with Chase (NYSE: JPM), building on the successful collaboration between Hyatt and Chase that rewards World of Hyatt cardmembers for stays across Hyatt’s global portfolio.
World of Hyatt remains the fastest-growing loyalty program in the global hospitality industry with more than 60 million members, growing at a rate of nearly 30% annually since 2017. Through its continued emphasis on member choice and recognition, World of Hyatt is one of the most valuable hospitality loyalty programs, with more than 40% more members per hotel compared to the next closest competitor. The result is highly engaged members who spend more, stay more, and book through direct channels more frequently than non-members.
“Our expanded agreement with Chase marks an exciting next chapter in how we grow, reward, and engage with our most loyal travelers,” said Mark Vondrasek, Chief Commercial Officer, Hyatt. “By deepening our collaboration, we’re creating more ways for Chase cardmembers to experience Hyatt’s global portfolio and for World of Hyatt members to be recognized beyond their stays – driving meaningful value for our guests, our owners, and our brands.”
Hyatt expects a significant increase in economics following the expanded agreement with Chase, driven by the expanded collaboration, the continued growth of World of Hyatt membership, the strength of Hyatt’s global portfolio of premium brands serving travelers with high disposable incomes, and Hyatt’s robust hotel room pipeline in sought-after destinations. The expanded collaboration is expected to drive additional stays to Hyatt properties from other Chase cardmembers via Chase Travel and Chase Ultimate Rewards. World of Hyatt Explorist status will be added as a benefit for top spending Chase Sapphire Reserve and Sapphire Reserve for Business cardmembers beginning in the middle of 2026. Hyatt will also continue to increase the number of luxury and premium brands, such as Park Hyatt and Alila, participating in The Edit by Chase Travel.
“We are proud to deepen our over 15-year relationship with Hyatt, expanding our collaboration across not only co-brand, but also our branded cards and Chase Travel,” said Allison Beer, Chief Executive Officer of Card & Connected Commerce, Chase. “The participation from Hyatt in our luxury hotel program, The Edit, and offering loyalty status to Sapphire Reserve cardmembers allows us to deliver even greater value and flexibility to our mutual customers when they stay at world-class Hyatt properties.”
The impact to adjusted EBITDA recognized by Hyatt related to the economics of the credit card programs and similar third-party relationships is expected to be approximately $50 million in 2025 and more than double to approximately $105 million in 2027, with anticipated continued growth in future years. Hyatt will receive upfront pre-tax cash totaling $47 million in the fourth quarter of 2025, which will be recognized within franchise and other fees over the life of the agreement. Additional financial details can be referenced at the end of this press release.
World of Hyatt credit cards provide cardmembers with more opportunities to earn and redeem at nearly 1,500 hotels and all-inclusive properties in the Hyatt portfolio and over 1,200 Mr & Mrs Smith properties around the world. World of Hyatt stands apart from other hospitality loyalty programs with clear, reliable value – offering cardmembers exceptional redemption benefits including a fixed award chart and choice in milestone rewards.
Additionally, Hyatt plans to expand its card portfolio as Hyatt and Chase continue to grow their relationship, building on the success of its current co-branded credit cards – the World of Hyatt Credit Card and the World of Hyatt Business Credit Card. The World of Hyatt credit card portfolio has experienced incredible growth with over 30% increase in card spend and over 25% increase in total cardmembers over the last two years. World of Hyatt cardmember benefits include:
World of Hyatt Credit Card & Business Card:
Up to 9 total points per $1 spent at Hyatt hotels (4 Bonus Points per $1 spent on qualifying purchases, plus 5 Base Points per eligible $1 spent for being a World of Hyatt member)
2 Bonus Points per $1 spent on fitness club and gym memberships
1 Bonus Point per $1 spent on all other purchases
Complimentary World of Hyatt Discoverist status
World of Hyatt Credit Card
2 Bonus Points per $1 spent on local transit and commuting, dining, airline tickets purchased directly from the airlines
1 free night award each year after your cardmember anniversary at any Category 1-4 Hyatt hotel worldwide and a second free night after you spend $15,000 on purchases in a calendar year
World of Hyatt Business Card
2 Bonus Points per $1 spent in your top three categories each quarter. Eligible categories are dining, shipping, airline tickets when purchased directly with the airline, local transit & commuting, social media & search engine advertising, car rental agencies, gas stations, internet, cable & phone services
Earn up to $100 in Hyatt credits each anniversary year. Spend $50 or more at any Hyatt property and earn $50 statement credits up to two times each anniversary year
To learn more about the World of Hyatt credit cards, please visit: https://world.hyatt.com/content/gp/en/rewards/hyatt-credit-card.html.
The term “Hyatt” is used in this release for convenience to refer to Hyatt Hotels Corporation and/or one or more of its affiliates.
About Hyatt Hotels Corporation
Hyatt Hotels Corporation, headquartered in Chicago, is a leading global hospitality company guided by its purpose – to care for people so they can be their best. As of June 30, 2025, the Company’s portfolio included more than 1,450 hotels and all-inclusive properties in 80 countries across six continents. The Company’s offering includes brands in the Luxury Portfolio, including Park Hyatt®, Alila®, Miraval®, Impression by Secrets, and The Unbound Collection by Hyatt®; the Lifestyle Portfolio, including Andaz®, Thompson Hotels®, The Standard®, Dream® Hotels, The StandardX, Breathless Resorts & Spas®, JdV by Hyatt®, Bunkhouse® Hotels, and Me and All Hotels; the Inclusive Collection, including Zoëtry® Wellness & Spa Resorts, Hyatt Ziva®, Hyatt Zilara®, Secrets® Resorts & Spas, Dreams® Resorts & Spas, Hyatt Vivid® Hotels & Resorts, Sunscape® Resorts & Spas, Alua Hotels & Resorts®, and Bahia Principe Hotels & Resorts; the Classics Portfolio, including Grand Hyatt®, Hyatt Regency®, Destination by Hyatt®, Hyatt Centric®, Hyatt Vacation Club®, and Hyatt®; and the Essentials Portfolio, including Caption by Hyatt®, Unscripted by Hyatt, Hyatt Place®, Hyatt House®, Hyatt Studios®, Hyatt Select, and UrCove. Subsidiaries of the Company operate the World of Hyatt® loyalty program, ALG Vacations®, Mr & Mrs Smith, Unlimited Vacation Club®, Amstar® DMC destination management services, and Trisept Solutions® technology services. For more information, please visit www.hyatt.com.
About World of Hyatt
World of Hyatt is Hyatt’s award-winning guest loyalty program uniting participating locations in Hyatt’s Luxury Portfolio, including Park Hyatt®, Alila®, Miraval®, Impression by Secrets, and The Unbound Collection by Hyatt®; the Lifestyle Portfolio, including Andaz®, Thompson Hotels®, The Standard®, Dream® Hotels, The StandardX, Breathless Resorts & Spas®, JdV by Hyatt®, Bunkhouse® Hotels, and Me and All Hotels; the Inclusive Collection, including Zoëtry® Wellness & Spa Resorts, Hyatt Ziva®, Hyatt Zilara®, Secrets® Resorts & Spas, Dreams® Resorts & Spas, Hyatt Vivid Hotels & Resorts, Sunscape® Resorts & Spas, and Alua Hotels & Resorts®; the Classics Portfolio, including Grand Hyatt®, Hyatt Regency®, Destination by Hyatt®, Hyatt Centric®, Hyatt Vacation Club®, and Hyatt®; and the Essentials Portfolio, including Caption by Hyatt®, Hyatt Place®, Hyatt House®, Hyatt Studios, and UrCove. Members who book directly through Hyatt channels can enjoy personalized care and access to distinct benefits including Guest of Honor, confirmed suite upgrades at time of booking, diverse wellbeing offerings, digital key, and exclusive member rates. World of Hyatt offers a variety of ways to earn and redeem points for hotel stays, dining and spa services, wellbeing focused experiences through the FIND platform; as well as the benefits of Hyatt’s strategic loyalty collaboration with American Airlines AAdvantage®. Travelers can enroll for free at hyatt.com, download the World of Hyatt app for android and IOS devices and connect with World of Hyatt on Facebook, Instagram, TikTok and X.
Forward-Looking Statements
Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements about the Company’s anticipated benefits from its expanded collaboration with Chase, planned credit card portfolio expansion, expected Adjusted EBITDA growth related to the economics of the credit card programs and other third-party relationships, plans, strategies, and financial performance, and prospective or future events and involve known and unknown risks that are difficult to predict. As a result, our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by us and our management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the effects that the announcement or pendency of the planned disposition of Playa’s owned real estate may have on us, the occurrence of any event, change or other circumstance that could give rise to the termination of the share purchase agreement for the disposition; the effects that any termination of the share purchase agreement for the disposition may have on us or our business; failure to successfully complete the planned disposition of Playa’s owned real estate; legal proceedings that may be instituted related to the planned disposition; significant and unexpected costs, charges or expenses related to the planned disposition of Playa’s owned real estate; inability to obtain regulatory or governmental approvals in connection with the planned disposition of Playa’s owned real estate or to obtain such approvals on satisfactory conditions, general economic uncertainty in key global markets and a worsening of global economic conditions or low levels of economic growth; the rate and pace of economic recovery following economic downturns; global supply chain constraints and interruptions, rising costs of construction-related labor and materials, and increases in costs due to inflation or other factors that may not be fully offset by increases in revenues in our business; risks affecting the luxury, resort, and all-inclusive lodging segments; levels of spending in business, leisure, and group segments, as well as consumer confidence; declines in occupancy and average daily rate; limited visibility with respect to future bookings; loss of key personnel; domestic and international political and geopolitical conditions, including political or civil unrest or changes in trade policy; the impact of global tariff policies or regulations; hostilities, or fear of hostilities, including future terrorist attacks, that affect travel; travel-related accidents; natural or man-made disasters, weather and climate-related events, such as hurricanes, earthquakes, tsunamis, tornadoes, droughts, floods, wildfires, oil spills, nuclear incidents, and global outbreaks of pandemics or contagious diseases, or fear of such outbreaks; our ability to successfully achieve specified levels of operating profits at hotels that have performance tests or guarantees in favor of our third-party owners; the impact of hotel renovations and redevelopments; risks associated with our capital allocation plans, share repurchase program, and dividend payments, including a reduction in, or elimination or suspension of, repurchase activity or dividend payments; the seasonal and cyclical nature of the real estate and hospitality businesses; changes in distribution arrangements, such as through internet travel intermediaries; changes in the tastes and preferences of our customers; relationships with colleagues and labor unions and changes in labor laws; the financial condition of, and our relationships with, third-party owners, franchisees, and hospitality venture partners; the possible inability of third-party owners, franchisees, or development partners to access the capital necessary to fund current operations or implement our plans for growth; risks associated with potential acquisitions and dispositions and our ability to successfully integrate completed acquisitions with existing operations or realize anticipated synergies; failure to successfully complete proposed transactions, including the failure to satisfy closing conditions or obtain required approvals; our ability to successfully complete dispositions of certain of our owned real estate assets within targeted timeframes and at expected values; our ability to maintain effective internal control over financial reporting and disclosure controls and procedures; declines in the value of our real estate assets; unforeseen terminations of our management and hotel services agreements or franchise agreements; changes in federal, state, local, or foreign tax law; increases in interest rates, wages, and other operating costs; foreign exchange rate fluctuations or currency restructurings; risks associated with the introduction of new brand concepts, including lack of acceptance of new brands or innovation; general volatility of the capital markets and our ability to access such markets; changes in the competitive environment in our industry, industry consolidation, and the markets where we operate; our ability to successfully grow the World of Hyatt loyalty program and manage the Unlimited Vacation Club paid membership program; cyber incidents and information technology failures; outcomes of legal or administrative proceedings; and violations of regulations or laws related to our franchising business and licensing businesses and our international operations; and other risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”), including our annual report on Form 10-K and our Quarterly Reports on Form 10-Q, which filings are available from the SEC. These factors are not necessarily all of the important factors that could cause our actual results, performance or achievements to differ materially from those expressed in or implied by any of our forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Estimated Financial Impact
Recognized by Hyatt related to the economics of the credit card programs and similar third-party relationships
(in millions)
FY25 Outlook
FY26 Estimate
FY27 Estimate
Franchise and other fees
$ 100
$ 90
$ 105
Other revenues1
$ 45
$ –
$ –
Other direct costs1
$ (90)
$ –
$ –
Adjusted G&A expenses1
$ (5)
$ –
$ –
Impact to Adjusted EBITDA2
$ 50
$ 90
$ 105
1As of the effective date of the amendment, the credit card programs are now part of our World of Hyatt loyalty program and as a result, amounts previously recognized within other revenues, other direct costs, and Adjusted G&A expenses, along with expected future benefits related to the expansion of the programs, will be recognized within revenues for reimbursed costs and reimbursed costs on our condensed consolidated statements of income (loss). License fee revenues will continue to be recognized within franchise and other fees within gross fees.
2Represents Adjusted EBITDA recognized by Hyatt related to the economics of the credit card programs and similar third-party relationships. The Company has not included a reconciliation of net income (loss) to Adjusted EBITDA related to the credit card programs as the adjustments are either not applicable or items that the Company cannot forecast with sufficient accuracy and without unreasonable efforts. For a reconciliation of consolidated net income attributable to Hyatt Hotels Corporation to Adjusted EBITDA, please refer to the “Financials” section of the Company’s Investor Relations website.
The Company’s estimates are based on a number of assumptions that are subject to change and many of which are outside the control of the Company. If actual results vary from these assumptions, the Company’s expectations may change. There can be no assurance that Hyatt will achieve these results.